Indications and uses
For relief of occasional constipation (irregularity). This product generally produces a stimulus and bowel movement in 2 to 15 minutes.
For relief of occasional constipation (irregularity). This product generally produces a stimulus and bowel movement in 2 to 15 minutes.
Adults and children 12 years of age and older (with adult supervision) one to three units daily. Children 2 years and over but not more than 12 years should consult a doctor prior to use and not exceed one unit daily (with adult supervision). Twist off and remove tip; Lubricate tip prior to insertion: Place a few drops of water or product on the shaft prior to insertion. Also apply one of these lubricants to the a...
Other Information Store at room temperature 15°-30° C (59°-86° F)
Active ingredient (per mini enema)
Docusate Sodium USP 283 mg
Benzocaine 20mg
Docusate Sodium USP 283 mg ............. Stool Softener Laxative
Benzocaine 20mg ................................ Anesthetic
For relief of occasional constipation (irregularity). This product generally produces a stimulus and bowel movement in 2 to 15 minutes.
For rectal use only. This is not a suppository. Do not take orally. Individuals with sensitivity to Benzocaine should not use this product.
Ask a doctor or pharmacist before use if you are presently taking mineral oil.
If pregnant or breast-feeding, ask a health professional before use.
Keep out of reach of children.
In case of accidental ingestion or overdose, get medical help or contact a Poison Control Center immediately.
Adults and children 12 years of age and older (with adult supervision) one to three units daily. Children 2 years and over but not more than 12 years should consult a doctor prior to use and not exceed one unit daily (with adult supervision).
Twist off and remove tip; Lubricate tip prior to insertion: Place a few drops of water or product on the shaft prior to insertion. Also apply one of these lubricants to the anus before inserting the enema. With steady pressure, gently insert the tube into the rectum with care to prevent damage to the rectal wall. Squeeze to empty the contents. Continue squeezing the tube until it is removed from the rectum. Remove the disposable tube and discard. A small amount of liquid may remain in the tube after use.
Positioning:
For best results, lay on the left side with knees bent.
Alternate Positions:
Other Information Store at room temperature 15°-30° C (59°-86° F)
Inactive Ingredients Polyethylene Glycol and Glycerin USP
Questions or Comments: 1-888-273-9734 or
www.enemeez.com
Manufactured by:
Enemeez, Inc., Phoenix, AZ 85050
Distributed by:
Alliance Labs, L.L.C
2515 E. Rose Garden Lane, Suite #1
Phoenix, AZ 85050
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 17433-9877-0 | ML - Milliliter | 17433-9877 | 2e9b0ac6-919d-4fe2-a8ba-a2b8c95ed351 | 1 | 2018-05-09 |
| 17433-9877-2 | ML - Milliliter | 17433-9877 | 0f3c3df0-f564-4e9a-9b9e-7083e97ea8fe | 1 | 2025-09-12 |
| 17433-9877-3 | ML - Milliliter | 17433-9877 | 53354c2d-cba7-4902-8a17-9cd8f7ede81b | 1 | 2013-02-13 |
| 17433-9877-5 | ML - Milliliter | 17433-9877 | 7b0c7f3e-bcf2-4dd1-b6d2-bb54d55b0209 | 1 | 2022-05-04 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| BENZOCAINE | ACTIVE INGREDIENT | U3RSY48JW5 | 3 | |
| DOCUSATE SODIUM | ACTIVE INGREDIENT | F05Q2T2JA0 | 3 | |
| BENZOCAINE | ACTIVE MOIETY | U3RSY48JW5 | 3 | |
| DOCUSATE | ACTIVE MOIETY | M7P27195AG | 3 | |
| GLYCERIN | INACTIVE INGREDIENT | PDC6A3C0OX | 3 | |
| POLYETHYLENE GLYCOLS | INACTIVE INGREDIENT | 3WJQ0SDW1A | 3 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 17433-9877 | 17433-9877-0, 17433-9877-3, 17433-9877-6, 17433-9877-5, 17433-9877-7, 17433-9877-2, 17433-9877-1, 17433-9877-4 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| BENZOCAINE | U3RSY48JW5 | ACTIB |
| POLYETHYLENE GLYCOL 300 | 5655G9Y8AQ | IACT |
| GLYCERIN | PDC6A3C0OX | IACT |
| DOCUSATE SODIUM | F05Q2T2JA0 | ACTIB |
| Version | Effective date | Source | Hydrated |
|---|---|---|---|
| 22 | 2026-03-25 | full-release | 2026-06-01 01:51:31 |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LIQUID / ORAL | 2400 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUPPOSITORY / RECTAL | 440 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUPPOSITORY / RECTAL | 440 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LIQUID / ORAL | 2400 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LIQUID / ORAL | 2400 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LIQUID / ORAL | 2400 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LIQUID / TOPICAL | 2.5 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LIQUID / TOPICAL | 2.5 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LIQUID / ORAL | 2400 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUPPOSITORY / RECTAL | 440 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUPPOSITORY / RECTAL | 440 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LIQUID / TOPICAL | 2.5 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LIQUID / ORAL | 2400 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LIQUID / ORAL | 2400 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUPPOSITORY / RECTAL | 440 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUPPOSITORY / RECTAL | 440 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LIQUID / ORAL | 2400 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LIQUID / ORAL | 2400 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUPPOSITORY / RECTAL | 440 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUPPOSITORY / RECTAL | 440 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LIQUID / TOPICAL | 2.5 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LIQUID / TOPICAL | 2.5 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUPPOSITORY / RECTAL | 440 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LIQUID / TOPICAL | 2.5 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LIQUID / TOPICAL | 2.5 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LIQUID / TOPICAL | 2.5 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LIQUID / TOPICAL | 2.5 %w/w |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| ENEMEEZ Plus | DOCUSATE SODIUM AND BENZOCAINE | Quest Products, LLC | 1670ca59-7275-4ac6-bef4-674a7b24c7b3 | 2026-06-30 | Warnings | 17433-9877-5 17433-9877-7 17433-9877-3 17433-9877-4 17433-9877-0 17433-9877-6 17433-9877-2 17433-9877-1 17433-9877 17433987701 17433987704 17433987702 17433987705 17433987700 17433987706 17433987703 17433987707 557c260c-c8fb-da2f-e063-6294a90a5501 1670ca59-7275-4ac6-bef4-674a7b24c7b3 |
Adverse event summaries are temporarily unavailable. Other product information remains available.